Actively Recruiting
The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.
Led by Institute of Cancer Research, United Kingdom · Updated on 2025-12-16
50
Participants Needed
1
Research Sites
898 weeks
Total Duration
On this page
Sponsors
I
Institute of Cancer Research, United Kingdom
Lead Sponsor
C
Cancer Research UK
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of the study is to determine if PET-CT imaging (using contrast recommended in clinical guidelines) is superior to combined bone scan and MRI/CT of the abdomen \& pelvis in detecting the increased incidence of metastasis (nodal/distant outside the pelvis) in men with prostatic carcinoma with mutations in any of the following germline DNA repair genes BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2, PALB2, ATM.
CONDITIONS
Official Title
The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed pathogenic germline mutation in BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2, PALB2, or ATM genes
- Male aged 18 years or older
- Diagnosed with prostate cancer and requiring staging imaging either at new diagnosis, biochemical progression after radical treatment over 6 months ago without current hormonal or chemotherapy treatment, or active surveillance with PSA doubling time of 6 months or less
You will not qualify if you...
- Diagnosis of another cancer (except basal or squamous cell skin cancer) within 5 years
- Known metastatic prostate cancer, local or distant
- Received any oncological treatment within the last 6 months
- Currently on investigational drug treatment
- Currently using steroids
- History of inflammatory or infectious diseases such as sarcoidosis, tuberculosis, or inflammatory bowel disease
- Contraindications to MRI including pacemakers, aneurysm clips, or claustrophobia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Genetics Unit, Royal Marsden Hospital
London, Sutton, Surrey, United Kingdom, SM2 5PT
Actively Recruiting
Research Team
R
Rosalind A Eeles, FRCP FRCR
CONTACT
E
Elizabeth K Bancroft, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here